Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

INBRX-101

Fusion protein · Protein replacement · developed by Inhibrx Biosciences

Phase 1 Most advanced trial (none active)

INBX Developer

1 Registered trials

What is INBRX-101?

INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein designed for alpha-1 antitrypsin deficiency (AATD). It combines AAT with an Fc domain to provide protein replacement therapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Fusion protein
Mechanism: Protein replacement
Therapy area: Respiratory
Developer: Inhibrx Biosciences, Inc (INBX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03815396	Phase 1	Alpha-1 Antitrypsin Deficiency	Completed	INBX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AATDAlpha-1 Antitrypsin Deficiency

More from Inhibrx Biosciences

Enristomig Phase 1 Ordastobart Phase 2/3 Ozekibart Phase 2

Sources

ClinicalTrials.gov NCT03815396

Updated Oct 3, 2026. Something wrong or missing? Report it on the INBX page.

Follow INBX, the company behind INBRX-101

See INBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INBX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z